Cardiovascular Disease
Statin therapy safely reduces the risk of vascular events
Published in Obesity and Diabetes Week, October 9th, 2006
In a recent review, scientists in England conducted a review "to summarize recent and ongoing randomized trials of statin therapy for the prevention of major vascular events. Four large-scale randomized trials have compared high-dose vs. standard doses of statin therapy among patients with coronary heart disease, and their results suggest that higher doses are more effective for preventing major vascular events, albeit with evidence of increased toxicity."
P.M. Kearney and C. Baigent working with the Clinic Trial Service Unit summarized, "There is now clear evidence that statin therapy is...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes & Obesity
Neuronal PTP1B regulates body weight, adiposity, and leptin action - Endocrinology
Appetite regulatory hormone responses to various dietary proteins differ by body mass index - Insulin Resistance
Cerebrocortical response to hyperinsulinemia is reduced in overweight humans - Obesity Pathogenesis
In obese, Tanner stage G1PH1 boys the inhibin B/FSH axis is activated early - Type 2 Diabetes
Obesity is a determinant of C-reactive protein levels and metabolic syndrome link in diabetes - Adipocytes
Sennidin stimulates glucose incorporation in rat adipocytes - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
